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A B S T R A C T
ANGPTL8 (Angiopoietin-like protein 8) is a newly identified hormone emerging as a novel drug target for
treatment of diabetes mellitus and dyslipidemia due to its unique metabolic nature. With increasing number
of studies targeting the regulation of ANGPTL8, integration of their findings becomes indispensable. This
study has been conducted with the aim to collect, analyze, integrate and visualize the available knowledge
in the literature about ANGPTL8 and its regulation. We utilized this knowledge to construct a regulatory
pathway of ANGPTL8 which is available at WikiPathways, an open source pathways database. It allows us
to visualize ANGPTL8’s regulation with respect to other genes/proteins in different pathways helping us to
understand the complex interplay of novel hormones/genes/proteins in metabolic disorders. To the best of
our knowledge, this is the first attempt to present an integrated pathway view of ANGPTL8’s regulation and
its associated pathways and is important resource for future omics-based studies.
© 2017 Elsevier Inc. All rights reserved.
1. Introduction
Metabolic syndrome (MetS) and diabetes mellitus (DM) are two
major health concerns worldwide and their prevalence is predicted
to increase significantly by the year 2030, due to global obesity
epidemic [1–3]. MetS is characterized by a multiplex of clinical
traits including obesity, dyslipidemia, insulin resistance, hyperten-
sion and hyperglycemia. On the other hand, DM is characterized
by hyperinsulinemia and hyperglycemia often coupled with diabetic
dyslipidemia. Insulin resistance and dyslipidemia are among com-
mon risk factors for developing DM, MetS and many other related
disorders. These metabolic disorders share related pathological ori-
gins embedded in dysfunctional lipid and carbohydrate metabolism.
Identification of the key molecular players in these pathological
conditions is required in order to increase our systems wide under-
standing and to find better drug targets for their treatment.
In one such effort, ANGPTL8 (Angiopoietin-like protein 8) was
identified as a novel hormone with unique metabolic nature through
* Corresponding author at: Research Centre for Modeling and Simulation - RCMS,
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experiments performed in a collaborative effort of Genetech and
Lexicon pharmaceuticals. The investigators performed a phenotypic
screening of 472 secreted and membrane proteins by creating a gene
knockout library of murine models in order to study their poten-
tial as a drug target [4]. In this study, ANGPTL8 was recognized as
one of the genes associated to the metabolic phenotypic trait. Their
data demonstrated that ANGPTL8 gene knockout mice model was
associated with decreased serum triglyceride levels as compared to
wild-type littermates. Further studies revealed its function in main-
taining lipid homeostasis and is now characterized to be involved in
both glucose and lipid metabolism. It was designated different names
such as lipasin [5,6], RIFL (refeeding induced in fat and liver) [7]
and betatrophin [8] in the subsequent attempts to characterize its
function. The name lipasin refers to one of its functions which is
to inhibit an enzyme LPL (lipoprotein lipase). LPL is a hydrolytic
enzyme which is involved in trafficking of lipoproteins and their
subsequent clearance [5,6]. The name RIFL refers to its expression
profile because it was induced upon refeeding after a certain period
of fast, predominantly in the liver and adipose tissue of the mice and
humans [7]. The name betatrophin refers to its functional ability to
induce the pancreatic beta cell proliferation demonstrated by Yi et al.
[8]. However, this role of ANGPTL8 has remained controversial and is
still being debated.
http://dx.doi.org/10.1016/j.ygeno.2017.06.006
0888-7543/© 2017 Elsevier Inc. All rights reserved.
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Increased serum ANGPTL8 has also been observed in several
diseases including DM, MetS and NAFLD (non-alcoholic fatty liver
disease) [9–12]. In this regard, inhibition of ANGPTL8 for reducing
the serum triglyceride levels and its overexpression for improving
glucose tolerance is being anticipated as a therapeutic strategy to
lower the TG (triglycerides) levels in dyslipidemia and as a glucose
lowering drug in DM, respectively [5,13-15]. However, knowledge
of its physiological mechanism of action, its gene regulation and
its functional characterization are prerequisites in order to exploit
the full potential of ANGPTL8 in future treatment regimens for DM
and/or dyslipidemia.
Different studies have investigated the molecular targets, regula-
tors and associated signaling pathways of ANGPTL8 to decipher its
physiological role. These studies partly elucidated its mechanism of
action and suggested that it plays a critical role in the metabolic
pathways maintaining whole-body homeostasis of glucose and fat
metabolism [8,13,14,16]. It is regulated by various factors includ-
ing feeding/fasting, caloric intake, thyroid hormone, insulin, glu-
cose, irisin, insulin receptor antagonists (S961, OSI-906), SREBP
(sterol regulatory element-binding protein) isoforms, LXR agonists,
ChREBP (carbohydrate-responsive element-binding protein), AMPK
(5′ adenosine monophosphate-activated protein kinase) and MAPK
(mitogen-activated protein kinase) signaling pathway [5,7-9,16-21].
There is a consensus from observations that ANGPTL8 is a down-
stream signaling entity in the insulin signaling pathway [7,8,13,22].
Its activation in the presence of both glucose and insulin is suggestive
of its regulation through a crosstalk mechanism mediated by glucose
and insulin regulated transcription factors.
Different pathway databases such as WikiPathways [23],
Reactome [24] and KEGG (Kyoto Encyclopedia of Genes and
Genomes) [25] maintain the regulatory information of genes in the
form of pathway diagrams. These pathway diagrams are used to
represent the regulatory information of the genes, proteins, and
metabolites in the order of their activation/inhibition and signal-
ing within the cells in response to various stimuli. These pathway
databases are an integral source of current analytical workflow of
different genomics based data analysis [26]. Updating these path-
way data repositories with new information is an essential part of
omics-data based studies.
At present none of the major pathway databases including
WikiPathways, Reactome and KEGG holds any interaction data
regarding ANGPTL8. Therefore, the current study has been con-
ducted with the aim to collect, analyze, integrate and visualize all
the available knowledge about ANGPTL8 and its regulation from the
literature. We present an updated summary of its gene structure,
protein structure, regulatory roles, and regulators. We also present
a literature curated pathway of ANGPTL8 regulation as a research
resource which is available online through WikiPathways (Pathway
Id: WP3915). The ANGPTL8 regulatory pathway was constructed
using PathVisio which is a software for pathway construction and
analysis [27,28]. This pathway captures all the regulatory interac-
tions of ANGPTL8 in associated signaling pathways described in
literature so far. Thus, to the best of our knowledge, this path-
way presents the first instance of integrating interaction data of
ANGPTL8. This pathway could aid future analytical studies using
omics approaches to elucidate its precise physiological mechanism
of action and unidentified interaction partners [29].
2. Methodology
The steps followed to collect, analyze, integrate and visualize
knowledge related to ANGPTL8 are illustrated in Fig. 1. A systematic
literature search was performed, in which research papers between
the years 2012 and 2016 were obtained in order to collect informa-
tion about the gene and protein structure and regulatory interactions
of ANGPTL8. The keywords “ANGPTL8”, “Angiopoitein-like protein
8”, “C19orf80”, “chromosome 19 open reading frame”, “betatrophin”,
“lipasin” and “RIFL” were used to select the relevant studies in
Google scholar and PubMed. The selected time filter is based on
the fact that functional characterization of ANGPTL8 started in the
year 2012. One hundred fifty three unique studies were filtered out
(Supplementary file 1) and selected in this step. However, the lit-
erature references with redundant and/or irrelevant information (as
per criteria discussed above) were not cited but can be viewed in
Supplementary file 1. In addition, the presence of ANGPTL8 in path-
ways was investigated by searching pathways databases including
WikiPathways, KEGG, and Reactome [23–25]. The results of the lit-
erature search and pathways database mining were used to design
the ANGPTL8 regulatory pathway. Importantly only those interac-
tions were selected which must have been reported for liver besides
other tissues/organs. The selected interactions should be experimen-
tally validated in at least one study while taking into account only
human, mouse and rat studies. The specie selection criterion is based
on the following facts:
• Rodent/mice models are the most extensively and reliably used
animal models to study the respective human mechanisms
due to a lot of factors especially their genome similarity with
humans (which is 99% [30]). However, the discussion of their
potential usage and/or limitations is out of scope of this study
and can be followed in [30–34].
• ANGPTL8 gene is an evolutionarily conserved gene among
mammals which is indicative of its class specific conserved
function. It has been reported to share 73% and 69% protein
sequence similarity with its closest homologs i.e. Mus musculus
and Rattus norvegicus, respectively [7,15].
• Most of the regulatory (interaction) data mined from literature
has already been verified for both human and mouse/rat and is
discussed in detail in the Results and discussion section.
PathVisio, a pathway editor and analysis tool, was used for the
construction of ANGPTL8 regulatory pathway [27,28]. It allows the
import and export of pathway files in multiple formats recognized
by different pathway/network analysis softwares. It also allows link-
ing the entities (gene, proteins or metabolites) and interactions with
respective public databases. The origin of each interaction was anno-
tated in the pathway using either pathway or literature database
identifiers. This allows the users of the pathways to trace back
the source data related to each interaction. Besides, the interaction
present in different species are illustrated with different arrow types
(illustrated in the legend of the pathway). Each entity (representing
either gene, protein or metabolite) was also linked to the respective
(gene, protein and metabolite) identifier in one of the public gene,
protein or metabolite databases. The pathway layout was optimized
after discussion among curators whereafter it was then deposited in
the WikiPathways with pathway id: WP3915. The WikiPathways is
an open-source pathway database maintaining pathways as dynamic
models which contains links to other resources [23]. It also allows
maintaining submitted pathways through updates, research commu-
nity feedback and corrections while preserving previous versions.
3. Results and discussion
An extensive summary of ANGPTL8 gene structure, protein struc-
ture, regulatory roles and regulators is presented as an update.
Furthermore, the ANGPTL8 regulatory pathway is described, dis-
cussing its sequence of signaling steps as captured in the pathway
(WP3915) submitted in WikiPathways (Fig. 3).
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Fig. 1. Methodology workflow: Literature and pathways database mining was performed to search all the available information on ANGPTL8. Selected interactions from this
information were then used to create the ANGPTL8 regulatory pathway using PathVisio. The pathway was then made available to the research community at WikiPathways
(Pathway Id: WP3915). The pathway is open for feedback, corrections and updates by the research community.
3.1. ANGPTL8 gene
The ANGPTL8 gene is present in the intron of the Dedicator
of Cytokinesis 6 (DOCK6) gene on chromosome 19 in humans
(http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=
core;g=ENSG00000130173) and on chromosome 9 in mouse
(http://www.ensembl.org/Mus_musculus/Gene/Summary?db=
core;g=ENSMUSG00000047822) It has been reported as a par-
alog of ANGPTL3 gene arisen due to a gene duplication event
where ANGPTL3 itself is present in the intron of DOCK7 gene [17].
Quagliarini et al. [17] identified four exons in the human gene [17]
and so far four transcripts of ANGPTL8 have been reported in
Ensembl databank (http://www.ensembl.org/Homo_sapiens/Gene/
Summary?db=core;g=ENSG00000130173). The two full length
transcripts encode 198 amino acids long proteins whereas the
two other isoforms encode shorter forms of the protein containing
99 and 58 amino acids long respectively (Fig. 2 (A)). The shorter
isoforms, lack the N-terminal amino acid residues and have been
reported as a possible cause of discrepancies in the measurement
of full-length ANGPTL8 transcripts in different studies in which
ELISA kits based on C-terminal antibodies were used (which would
measure both full-length and C-terminal fragments) [35]. Tseng et
al. reported the presence of several thyroid hormone response ele-
ments (TREs) in the upstream region of ANGPTL8 gene [16]. Thyroid
hormone receptors alpha (THR-a) and beta (THR-b) belong to the
class of nuclear receptors which mediate the transcription of their
respective target genes by binding to these TREs. Fu et al. reported
the presence of a ChRE (carbohydrate response element) in the
promoter region of ANGPTL8 gene which is regulated by ChREBP
(carbohydrate response element binding protein) [9].
Several non-synonymous SNPs (single-nucleotide polymor-
phisms) exist in the ANGPTL8 gene (http://www.ensembl.
org/Homo_sapiens/Gene/Variation_Gene/Table?db=core;g=
ENSG00000130173). However, only two functional variant SNPs
associated with ANGPTL8 have been published including rs2278426
(http://www.ensembl.org/Homo_sapiens/Variation/Explore?db=
core;g=ENSG00000130173;v=rs2278426) and rs145464906
(http://www.ensembl.org/Homo_sapiens/Variation/Mappings?db=
core;g=ENSG00000130173;v=rs145464906). The SNP rs2278426
corresponds to an alteration of an arginine reside to tryptophan at
position 59 and its functional variant has been associated with lower
HDL (high density lipoprotein) and LDL (low density lipoprotein)
cholesterol plasma levels and higher fasting plasma glucose in peo-
ple with different ethnicities [17,22,36-39]. The SNP rs145464906
corresponds to an alteration of a glutamine amino acid residue to
stop codon at amino acid position 121 and results in a truncated
form of protein [40].
3.2. Protein
ANGPTL8 belongs to ANGPTL family which consists of eight
members (ANGPTL1 to ANGPTL8). ANGPTL1-ANGPTL7 share a very
similar structure consisting of an amino terminal domain (coiled-
coil) and a carboxy terminal (fibrinogen-like) domain attached
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Fig. 2. (A) Gene structure of four transcripts (http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000130173) of the human ANGPTL8 gene (created
using Exon-Intron Graphic Maker (http://wormweb.org/exonintron)). ANGPTL8-001, and ANGPTL8-201 transcribe protein sequences of 198 amino acids whereas ANGPTL8-003
and ANGPTL8-004 transcribe protein sequences of 99 and 58 amino acid length, respectively. (B) Protein structure of ANGPTL8. ANGPTL8 is 198 amino acids long with a predicted
signal peptide, two coiled coil domains and several protein modifications. It also contains a SE1 motif which is a conserved sequence motif between ANGPTL 3, 4 and 8 and is
required for inhibition of LPL.
with a linker region. ANGPTL8 has a different structure from all
other protein family members as it possesses only the coiled-
coil domain [17,41]. All members of ANGPTL protein family seems
to serve multiple biological roles in maintaining different aspects
of metabolism, angiogenesis and hematopoiesis (more details are
reviewed in [41]). ANGPTLs were recognized as orphan ligands due to
lack of binding with the TIE1 (tyrosine kinase with immunoglobulin-
like and EGF-like domains 1) receptors unlike Angiopoietins protein
family. However, ANGPTL2, ANGPTL5 and ANGPTL7 have been now
reported to interact with LILRB2 (leukocyte immunoglobulin-like
receptor B2) and PIRB (immunoglobulin-like) receptors present on
hematopoietic stem cells (HSCs) [42]. The ability of ANGPTL8 to
stimulate CD45+ hematopoietic-derived cell differentiation raises
a possibility that it might also interact with the same receptors to
perform this function [43].
Protein sequence analysis of ANGPTL8 showed sequence con-
servation across mammals indicating its class specific functional
importance [8,44]. Furthermore, the protein sequence of ANGPTL8
between mouse and humans share 73% identity suggesting evo-
lutionary conservation [5]. Phylogenetic analysis based on protein
sequence alignments revealed close association of ANGPTL8 with
ANGPTL3 and ANGPTL4 [5]. It shares 50% amino acid similarity with
N-terminal domain of ANGPTL3 and significant sequence similarity
with a stretch of 100 amino acids of ANGPTL4. ANGPTL8 also has
been demonstrated to possess the conserved SE1 (Specific Epitope
1) motif which is necessary and sufficient for inhibition of LPL by
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Fig. 3. The ANGPTL8 regulatory pathway (pathway id: WP3915 (http://www.wikipathways.org/index.php/Pathway:WP3915)). a) Insulin receptor induced IS signaling events; b) AKT activation and signaling; c) FOXO signaling; d)
mTORC1 signaling; e) LXR/SREBP signaling; f) glucose transport and metabolic signaling; g) thyroid hormone signaling; h) MAPK signaling; i) ANGPTL8 signaling.
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ANGPTL3 and ANGPTL4 demonstrated through both in vivo and in
vitro experiments [45,46].
ANGPTL8 protein sequence encompasses a signal peptide (1–21
a.a) at the N-terminal region indicative of its secretory nature [8,44].
Two coiled-coil domains are also predicted to be present in the
protein structure [8,45]. Several N-myristoylation sites and casein
kinase phosphorylation sites on the N-terminal of ANGPTL8 are
predicted in [15] (Fig. 2 (B)). These protein modifications are indica-
tive of its membrane anchoring ability and rapid signal response,
respectively.
3.3. Tissue expression and cellular localization
The metabolic tissues restricted expression profile of ANGPTL8
is suggestive of its essential role in metabolism. The tissue expres-
sion profile of ANGPTL8 demonstrated by R. Zhang showed highest
expression in the liver, BAT (brown adipose tissue) and subcuta-
neous fat of mice out of twenty tissues tested whereas in humans
only liver showed predominant expression out of forty-eight tis-
sues tested [5]. Further experiments from this group revealed its
thermoregulated nature by investigating its link with BAT [6].
Their data revealed an increase in expression of ANGPTL8 at low
temperature in BAT of mice. Ren et al. demonstrated a similar
expression profile for mice whereas in humans it was consid-
erably expressed in both liver and WAT (white adipose tissue)
out of the four tissues tested [7]. Data from the Quagliarini et
al. shows the highest expression of ANGPTL8 in liver along with
comparable expression profile in brain and WAT out of seven-
teen tissues tested [17]. The expression profiles evaluated using
Human Protein Atlas (available from http://www.proteinatlas.org/
ENSG00000130173-C19orf80/tissue) shows the protein expression
of ANGPTL8 to be enriched in liver and adipose tissue whereas kidney
and breast tissue also show certain expression levels (Supplementary
Fig. S1) [47].
Under basal physiological conditions, ANGPTL8 expression has
been demonstrated to be induced upon re-feeding and reduced
upon fasting. Data of Ren et al. shows approximately 80 and 12
fold increase of the expression in WAT and liver upon re-feeding
experiments conducted on fasted mice [7]. This was confirmed in
several transcriptomics studies (both human and mice) in which
nutritional status such as re-feeding after 6/12 h fast and re-feeding
after a period of low-calorie diet was investigated [7]. Several
mouse models such as that of obesity (ob/ob), diabetes (db/db), high
fat fed (HFD), gestational mice and the insulin resistance mouse
model treated with the insulin receptor antagonist S961 have also
shown elevated expression of ANGPTL8 [5,8]. ANGPTL8 is a secre-
tory protein as assessed due to its presence in human and mice
serum along with the existence of a predicted signal peptide in
its N-terminal region [8]. However, cytoplasmic ANGPTL8 has been
demonstrated to exist as vesicle-like structures of various sizes
around and within the lipid droplets and endoplasmic reticulum
associated compartments [16]. The golgi apparatus and nucleoli
are assessed as the sub-cellular locations of ANGPTL8 by using
Human Protein Atlas (available from http://www.proteinatlas.org/
ENSG00000130173-C19orf80/subcellular) [47].
3.4. Role in lipid metabolism
ANGPTL8 has been characterized as an important regulator of
lipid metabolism but the exact mechanisms of actions still need to
be delineated. Serum triglycerides level were increased in ANGPTL8
over-expressed mice models and were decreased in ANGPTL8 knock-
out mice models [5,7,17,48]. Further investigations revealed that it
plays a role in substrate partitioning through inhibition of LPL dur-
ing fasting-feeding metabolic transition [5,48]. LPL is a rate-limiting
enzyme involved in hydrolysis of dietary lipids and their subse-
quent uptake in peripheral tissues. The mechanism of action behind
increased serum triglyceride levels in the presence of ANGPTL8 is
explained by its ability to inhibit LPL and subsequently reduce the
serum triglycerides clearance [5]. Wang et al. further clarified the
role of ANGPTL8 in reducing the postprandial LPL activity in oxida-
tive tissues (heart and skeletal muscles) in order to direct the serum
triglycerides for uptake by adipose tissues in energy favoring con-
ditions [48]. On the other hand, fasting increases the LPL activity
in oxidative tissues due to down-regulation of ANGPTL8 and directs
the triglycerides towards them. By contrast, Ren et al. demonstrated
a lipogenic role of ANGPTL8 through a series of in-vitro and in-
vivo experiments [7]. Their data demonstrated positive correlation
of ANGPTL8 expression with the process of adipogenesis in both
mice and humans whereas ANGPTL8 null mice showed reduced lipid
content in adipocytes during adipogenesis. This is also in correspon-
dence with the phenotypic triglycerides levels observed in ANGPTl8
over-expressed and null mice, respectively. However, the mechanis-
tic protein partner of ANGPTL8 in adipogenesis and their regulation
is still a quest.
In an independent study, Tseng et al. demonstrated that thyroid
hormone stimulates the up-regulation of ANGPTL8 in an attempt to
identify the genes which are involved in autophagy and are also reg-
ulated by T3 [16]. Their data revealed another role of ANGPTL8 in
lipid metabolism which is to activate the process of autophagy by
inducing catabolism of lipid droplets in the liver cells. Their experi-
ment with over-expression and gene silencing of ANGPTL8 supports
its role in the maintenance of intracellular lipid homeostasis in liver.
Zhang et al. demonstrated that the Ras/c-Raf/MAPK signaling path-
way regulates the expression of ANGPTL8 in hepatic, fat and pan-
creatic beta cells [19]. It was reported as a stress response mediated
protein which can reduce the expression of ATGL (adipose triglyc-
eride lipase) by induction of early growth response transcription
factor (Egr1). This study provides another connection of ANGPTL8 in
maintenance of lipid homeostasis.
Different mouse models of obesity and diabetes including db/db
(diabetic), ob/ob (obese), HFD (high fat fed) and insulin resis-
tance mouse model (using insulin receptor inhibitors S961 and
OSI-906) have shown the elevated expression of ANGPTL8 in the
liver [5,8,20]. Besides, altered serum levels of ANGPTL8 have also
been reported in obesity, DM type 2, DM type 1, MetS and NAFLD
in humans [9-12,49-51]. In an independent study the positive cor-
relation of ANGPTL8 with atherogenic lipid profile in diabetic (type
II) patients was also observed [52]. Collectively, the role of ANGPTL8
in lipid metabolism and its elevated levels in associated disorders
are suggestive of its therapeutic potential in reduction of hyper-
triglyceridemia through its inhibition. However, more studies are
required in order to identify the potential interacting partners and/or
regulators of ANGPTL8 in lipid metabolism and its association with
other genes/proteins/pathways to further evaluate its therapeutic
potential in related disorders.
3.5. Role in glucose metabolism
Several studies have reported the role of ANGPTL8 in glucose
metabolism which increases its significance as possible drug target.
Interestingly, its overexpression was demonstrated to improve glu-
cose tolerance in the livers of mice [8,13]. Fu et al. demonstrated
the positive correlation between ANGPTL8 expression and glucose
in diabetic setting implying the necessity and possibility of glucose
regulation through ANGPTL8 [9]. This study also pointed out the pos-
sibility of ANGPTL8 to be a glucose regulated gene by describing the
presence of a ChREBP binding site in its promoter region. ChREBP
is a glucose mediated transcription factor and plays a significant
role in both glucose and lipid metabolism. In order to further eluci-
date its role in glucose metabolism, Guo et al. performed a series of
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experiments using transgenic human liver cell lines with ANGPTL8
over expression and knockout. Their data revealed that ANGPTL8
enhances the glucose lowering effect of the insulin signaling path-
way by AKT-GSK3b and/or AKT-FOXO1 branch [13]. Overall, a model
of ANGPTL8 activation via the insulin signaling pathway which helps
to alleviate insulin resistance through enhancing the phosphoryla-
tion of AKT, FOXO and GSK3-b is supported [13]. Their data revealed
that ANGPTL8 could phosphorylate AKT at serine 473, subsequently
allowing glycogen synthesis and inhibiting gluconeogenesis. Above
studies implicate the beneficial role of ANGPTL8 in improving glu-
cose tolerance in diabetic subjects. However, its drug potential in
diabetes as (glucose lowering drug) cannot be fully assessed with-
out having the comprehensive knowledge of its gene regulation and
its downstream target proteins which necessitates viewing it with
a systems perspective. The systems view of ANGPTL8 would allow
us to see the regulation of ANGPTL8 relative to other genes/proteins
present in different pathways. It would subsequently make it easier
to assess its pathogenic role by allowing us to visualize the regula-
tory mechanism of ANGPTL8 with respect to other genes/proteins
involved in the different diseases.
3.6. Role in pancreatic beta cell proliferation
Pancreatic beta cell repopulation is one of the anticipated treat-
ments for both diabetes type 1 and type 2 patients. In this regard,
ANGPTL8 emerged as one of the possible drug targets due to its high
pancreatic beta cell proliferative specificity and significant magni-
tude of proliferation [8]. Yi et al. demonstrated the over expression of
ANGPTL8 in all of the typical models of compensatory pancreatic beta
cell proliferation such as ob/ob (obesity), db/db (diabetes type II), and
gestational mice along with a new insulin resistance mouse model
(created by induction of insulin receptor antagonist S961). However,
the expected potential of ANGPTL8 could not be successfully con-
firmed when applied on human islets in the transplant setting [53].
Later on, Gusarova et al. demonstrated the inability of ANGPTL8 as a
stimulator of pancreatic beta cell proliferation by conducting knock-
down experiments in the insulin resistance (S961 induced) mouse
model [54]. Since then, the role of ANGPTL8 in pancreatic beta cell
proliferation has been heavily debated. There are several studies
which still support the role of ANGPTL8 in pancreatic beta cell pro-
liferation (such as [55]) and others contradict it (such as [43]). The
study by Chen et al. reported that injecting the human ANGPTL8
directly into the islets of mice increases replication of pancreatic beta
cells [55]. Their data supports the role of ANGPTL8 in diabetic set-
ting for both type 1 and type 2 patients since STZ (Streptozotocin)
induced mice showed alleviation if not complete reversal of the dis-
ease. However, Cox et al. demonstrated the anti-proliferative role of
ANGPTL8 along with explaining the basis of associated discrepan-
cies [43]. Their study revealed that in mice intravenous injection of
ANGPTL8 stimulated the CD45+ hematopoietic-derived cell prolifer-
ation, instead of pancreatic beta cells. They also explained that differ-
ent quantification methods were used for measuring the pancreatic
beta cells in previous studies investigating the role of ANGPTL8 in
pancreatic beta cell proliferation which was one reason for resultant
discrepancies previously. Overall, a systems view of ANGPTL8 gene
regulation can clarify the contrasting results of different studies.
3.7. Regulators of ANGPTL8
A set of positive and negative regulators of ANGPTL8 have been
demonstrated in different studies (Table 1). This overview is man-
ually curated exhaustively for all of the regulators playing a role in
hepatic expression of ANGPTL8 which is later used for making the
interactive pathway in this study.
The expression of ANGPTL8 is nutritionally regulated in humans
and mice. Refeeding increases the expression of ANGPTL8 while
fasting suppresses its activation [5,7]. Metabolically active organs
including liver WAT, and BAT are the predominant key expression
sites in both humans and mice [5,7,17]. Besides, high fat diet induced
obese mouse model and obesity in humans have also been char-
acterized to up-regulate its expression [7,9]. The overall expression
profile of ANGPTL8 has been positively associated with processes
promoting energy storage processes such as regulating postpran-
dial lipid traffic, adipogenesis, glycogen synthesis and negatively
associated with processes promoting energy consumption such as
gluconeogenesis [5,7,8,13,16,17]. Insulin is a key metabolic enzyme
coordinating the nutritional signals to regulate these processes in
liver and has also been demonstrated to increase the expression of
ANGPTL8 in human liver cell lines in the presence of glucose [13].
Ren et al. also reported through their in-vivo and in-vitro experiments
that insulin in the presence of glucose up-regulates its expression
in human and mice fat cells [7]. Activation of ANGPTL8 specifi-
cally in the presence of both insulin and glucose is indicative of a
crosstalk mechanism between insulin and glucose stimulated pro-
cesses to regulate its expression. Several downstream regulators of
insulin and glucose discussed below might provide clues to such a
mechanism.
Carbohydrate response element-binding protein (ChREBP) is a
glucose stimulated transcription factor involved in energy home-
ostasis. It binds to specific sequences on the promoter region of gene
known as carbohydrate responsive elements (ChRE). The data of Fu et
al. reveals the presence of ChRE on the ANGPTL8 promoter [9]. They
also pointed out towards another study where the binding of ChREBP
to the ANGPTL8 promoter in HepG2 cells was demonstrated [56].
However, further studies are required to verify this interaction for
activation of ANGPTL8. Sterol regulatory element-binding proteins
(SREBPs) are important integrators of nutritional and energy avail-
ability with cholesterol and fatty acid metabolism. SREBP-1a and
SREBP-2 were demonstrated to modulate the expression of ANGPTL8
in livers of mice [17] whereas SREBP-1c was demonstrated to acti-
vate ANGPTL8 in human liver cell lines [18]. Liver X receptors
(LXRs) are important regulators of cholesterol, fatty acid, and glucose
homeostasis. LXR agonists have been reported to up-regulate the
expression of ANGPTL8 in both mouse and human livers in separate
studies [17,18]. Oxysterols (cholesterol metabolites) are the ligands
of LXRs which belong to a class of nuclear receptors and make het-
erodimers with RXR to regulate gene transcription. LXR is itself under
regulation of the insulin signaling pathway and indirectly regulated
by glucose as well [57]. LXR is also involved in crosstalk with other
nuclear receptors including thyroid hormone receptor [58]. Thy-
roid hormone through induction of thyroid hormone receptors was
demonstrated to up-regulate the expression of ANGPTL8 in human
liver cell lines [16]. It is of note that intracellular thyroid hormone
activation is itself under control of nutritional stimulus dependent
processes mediated by insulin signaling reported in [59]. Zhang et al.
reported an activation mechanism for ANGPTL8 via the RAS-MAPK
pathway upon amino acid deprivation mediated stress [19]. Their
data indicates that ANGPTL8 upon activation through RAS/MAPK
induces ERK expression which suppresses ATGL and plays a role in
lipid metabolism. The experiments of the Melton group reported on
a mouse model where S961 (an antagonist of the insulin receptor)
induced expression of ANGPTL8 up to 4 fold in the liver of mice [8].
Kaestner et al. also found a similar increase up to 5 fold in the liver of
mice on treatment with S961 [53]. S961 induces phenotype of insulin
resistance causing hyperinsulinemia and hyperglycemia in reported
mouse model. Thus S961 induced ANGPTL8 could be linked to the
earlier discussion on existence of a crosstalk mechanism between
insulin and glucose mediated metabolic processes for its regulation.
The negative regulators of the ANGPTL8 include fasting and AMPK
in liver and fasting, TNF-alpha and forskolin in adipose tissue so
far [5-7,17,18]. AMPK was demonstrated to induce the suppression
of ANGPTL8 through activation of PPAR-alpha [18]. This interaction
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Table 1
Literature curated list of positive and negative regulators of ANGPTL8 in liver. x = stimulation; k = inhibition; NE = no effect; NR =
regulator not yet reported for liver.
S. no. Name Expression in humans Expression in mouse References
1 Feeding x x [5,7,17]
2 Thyroid hormone x NR [16]
3 Insulin in the presence of glucose x NR [7,13]
4 ChREBP x NR [49,56]
5 Srebp-1a, Srebp-2 NR x [17]
6 Srebp-1c x NE [17,18]
7 LXR agonist x x [17,18]
8 Amino acids deprivation (stress) x x [19]
9 S961 (insulin receptor antagonist) NR x [8]
10 AMPK k NR [18]
11 Fasting k k [5,7,17]
is also well connected with nutritional regulation of ANGPTL8 where
fasting was shown to suppress ANGPTL8 expression.
The pathways revealed to be relevant to the expression
of ANGPTL8 include insulin signaling pathway [4,31], lipid
metabolism [5,7,17,48], glucose metabolism [8,9,13], autophagy in
liver [16], adipocytes differentiating pathway [7] and ERK signal
transduction pathway [19].
3.8. ANGPTL8 regulatory pathway
The complete ANGPTL8 regulatory pathway designed in this
study is presented in Fig. 3. The ANGPTL8 regulatory path-
way is available at WikiPathways (http://www.wikipathways.org/
index.php/Pathway:WP3915) making it accessible worldwide. The
pathway approach used for construction of the ANGPTL8 regulatory
pathway has been previously used to design the complete SREBP
regulation pathway in [60]. All the regulatory interactions in the
ANGPTL8 regulatory pathway are annotated with respective PubMed
ids of supporting studies which allows easy access to the source data.
In addition, the interactions present in only mouse/rat are depicted
with a dashed line. This visualization strategy aims to clarify the
distinction between human and mouse/rat interactions. The impact
of ANGPTL8 in lipid and glucose metabolism seems to be under
the complex regulation of the proteins working downstream of the
insulin signaling (IS) pathway. Therefore, the newly designed hepatic
ANGPTL8 regulatory pathway includes an updated version of the IS
pathway integrated with the known regulators of ANGPTL8 (Table 1).
Overall, the pathway represents an up-to-date curated interactive
pathway capturing the known regulatory behavior of ANGPTL8 in
glucose and lipid metabolic signaling pathways. The ANGPTL8 regu-
latory pathway is divided into eight subsections that are highlighted
with different colors in the pathway diagram illustrated in Fig. 3. The
biological evidence and literature for each subsection are explained
below in more detail.
The IS pathway coordinates metabolic responses to varying cel-
lular nutrient levels. IS pathway has two major branches involved
in either metabolic programming or growth/proliferation of the
cells. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B
(AKT/PKB) pathway is involved in mediating metabolic effects such
as uptake of glucose, protein and glycogen synthesis, lipid storage
and breakdown while the mitogen-activated protein kinases (MAPK)
pathway is associated with cellular growth processes such as gene
expression, cell motility, cell proliferation, cell survival and differ-
entiation. The regulators of ANGPTL8 belong to different branches
of the IS pathway which explains the complex results and findings
associated with ANGPTL8 in literature so far.
3.8.1. Insulin receptor mediated insulin receptor substrate signaling
Binding of insulin to the insulin receptor (IR) initiates the IS
pathway. The IR belongs to the tyrosine receptor kinase family of
proteins which upon ligand (insulin) binding result in autophospho-
rylation of various tyrosine residues in their intracellular tyrosine
kinase (TK) domain. The activated (phosphorylated) receptor has a
diverse set of substrates including isoforms of Shc (p46Shc, p52Shc)
and Insulin Receptor Substrates (IRS1, IRS2, IRS3, IRS4) [61]. IRS1
and IRS2 are found in most of the tissues whereas the expression
of IRS4 is tissue specific (brain, liver, kidney and thymus). IRS3
is only present in rodents [62]. IRS are cytoplasmic adapter pro-
teins which are recruited to tyrosine phosphorylated IR through
their PH/PTB domains and are phosphorylated at multiple tyrosine
residues in C termini [62]. The phosphorylated IRS is able to act as
a signaling protein with multiple downstream effectors including
phosphoinositide 3-kinase (PI3K), SHP2 and GRB.
3.8.2. AKT activation and signaling
IRS phosphorylates PI3 K upon binding which is then able to
catalyze the conversion of Phosphatidylinositol (4,5)-bisphosphate
(PIP2) to Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [61]. Next,
PIP3 recruits phosphoinositide-dependent kinase-1 (PDK1) and its
substrate kinase AKT to the plasma membrane to facilitate the prox-
imity required for the phosphorylation event [63]. The activation of
AKT requires two independent phosphorylation events for its max-
imal activity, i.e. at threonine 308 (T308) within the T loop of its
catalytic domain and at serine 473 (S473) within the hydropho-
bic motif located in a C-terminal which is a non-catalytic region
of the enzyme [64]. There is a broad consensus that PDK1 [65,66]
and mTORC2 [67] mediate the T308 and S473 phosphorylation of
AKT, respectively. However, the sequence of events in full activation
of AKT was recently demonstrated and fine-tuned in the canoni-
cal IS pathway [68]. According to this model, PDK1 phosphorylates
AKT at T308 in the kinase regulatory loop which in turn phos-
phorylates Sin1. Sin1 is an important protein member of mTORC2
complex and is required for its activation. mTORC2 upon activation
mediates a positive feedback loop to phosphorylate AKT at S473.
Recently, a study by Guo et al. have reported that ANGPTL8 could
also promote the phosphorylation of AKT at S473 in the presence
of both insulin and glucose using HepG2 cell line [13]. Their data
demonstrated the respective increase of phosphorylated forms of
GSK3-b and FOXO under AKT (S473) signaling and their respective
regulation of glycogen synthesis and gluconeogenesis. This interac-
tion is also supported by the experiments of Yi in which improved
glucose tolerance was observed in mice injected with ANGPTL8 as
compared to control-injected mice [8]. Other regulators of AKT at
S473 include DNA-dependent protein kinase (DNA-PK), ILK, tumor
necrosis alpha (TNF-a) and IB kinase4 and TANK-binding kinase 1
(IKK4/TBK1) through DNA damage, inflammation and cell survival
pathways, respectively [69]. However, none of these regulators have
been included in the ANGPTL8 regulatory pathway in order to avoid
unnecessary enrichment of the pathway.
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Both phosphorylations of AKT mediate functional division in the
role of AKT and affects its substrate diversity [69,70]. T308 phos-
phorylation of AKT is sufficient without a need for S473 to activate
mTORC1 [71]. On the other hand, S473 phosphorylation of AKT is
reported to mainly regulate FOXO transcription factors, GSK3-beta
and glucose uptake [69].
3.8.3. FOXO signaling
FOXO proteins are the regulators of insulin mediated control of
gluconeogenesis and glycogenolysis through transcription of impor-
tant enzymes involved in these processes including G6Pase, PEPCK
and FBP [72]. Besides, they also transcribe IR, Insulin growth factor
receptors (IGFR), IRS2, rictor and sestrin3 and regulate IS [69,73,74].
3.8.4. mTORC1 signaling
AKT activates mTORC1 by inactivating tuberous sclerosis protein
2 (TSC2) and thus relieving it from inhibition of RHEB. The substrates
of mTORC1 include eukaryotic translation initiation factor 4E binding
protein 1 (4EBP1), and ribosomal protein S6 kinase, 70 kDa, polypep-
tide 1 (S6K1) which are involved in protein synthesis and transla-
tional regulation. S6K1 is able to inhibit the IRS and forms a negative
feedback control circuit on IS [75]. Besides, it also up-regulates the
expression of LXR (Liver X receptor) which transcribes several genes
involved in cholesterol metabolism, lipogenesis, steroid metabolism
and drugs metabolism (Fig. 3). LXR also up-regulates the expres-
sion of ANGPTL8 possibly through a SREBP dependent mechanism
in liver [18]. Lee et al.reported an increased expression of ANGPTL8
upon treatment with LXR agonists palmitic acid, tunicamycin and
T0901317. However, this activation was reduced upon inhibiting the
SREBP1 expression through siRNA transfection [18]. Its reduced lev-
els observed upon treatment with AICAR (an activator of AMPK) are
suggestive of its inhibition to be dependent on AMPK [18]. LXR is
itself negatively regulated by AMPK and SREBP-1c [76,77].
3.8.5. Glucose transport and metabolism
Glucose uptake is mediated by the CBL arm of the IS pathway [78].
Intracellular glucose transport and subsequent metabolism is regu-
lated by multiple genes which are discussed in detail in [78]. ChREBP
is a glucose responsive transcription factor and is an important reg-
ulator of hepatic lipogenesis. It is post-translationaly regulated by
substrates of glycolysis (glucose breakdown) through X-5-p (xylu-
lose 5-phosphate) and G-6-p (glucose-6-phosphate) metabolic path-
ways [79]. X-5-p and G-6-p are phosphometabolites which tend to
remove inhibitory phosphorylation of ChREBP (through activating
PP2A) and increase its nuclear translocation, respectively [79,80].
The transcriptional regulation of ChREBP is mainly demonstrated to
be to be maintained by LXR and THR transcription factors [80]. Up-
regulation of ANGPTL8 in presence of glucose has been pointed out in
several studies [8,9,13]. In this context, ANGPTL8 was demonstrated
to contain a ChREBP binding site (−398 to −382) in the promoter
region [9]. In an independent study (ANGPTL8 was not the focus of
the study though), ChREBP was also observed to bind to the promoter
region of ANGPTL8 in human liver cell line [56]. These observations
support the role of ChREBP in positive regulation of ANGPTL8.
3.8.6. Thyroid hormone signaling
Tseng et al. reported that ANGPTL8 is transactivated by T3 stim-
ulation in human liver cell lines (HepG2 and Huh7) [16]. Their data
supports a model where it is transcribed through thyroid hormone
receptors heterodimerized with RXRA. Thyroid hormone receptors
alpha and beta belong to a class of steroid/nuclear hormone recep-
tors super family of ligand dependent transcription factors. These
receptors recognize and bind to the specific DNA elements known as
thyroid hormone response Elements (TREs) and make dimers with
either themselves or with RXRA. The absence of ligand allows them
to recruit co-repressor and in turn repress the expression of the
respective genes. Ligand binding of these receptors allows the dis-
sociation of co-repressors and initiates the transcription. Tseng et
al. also demonstrated the presence of several potential TREs in the
promoter region of the ANGPTL8 sequence [18]. In their study, the
physiological function of ANGPTL8 was revealed to promote the lipid
metabolism through T3 in order to regulate the autophagic flux of
lipid droplets. T3 is an important regulator of energy expenditure
and affects several genes involved in cholesterol and carbohydrate
metabolism [81]. The expression of serum and intracellular T3 is
itself under nutritional regulation through IS pathway which allows
induction of DIO2 enzyme [59]. The study by Lartey et al. revealed
insulin mediated activation of thyroid hormone activation by reliev-
ing the FOXO mediated repression of DIO2 in MSTO-211H cells and
in the livers of LIRKO (Liver specific Insulin Receptor Knockout)
and LIRFKO (Liver specific Insulin Receptor and FOXO1 Knockout)
mice [59]. DIO2-mediated T3 conversion is a major pathway in the
regulation of TH metabolism [59,81]. Their study demonstrated the
coupling of nutrient availability with thyroid hormone activation
via the PI3k-mTORC2-FOXO pathway implying important metabolic
consequences.
3.8.7. MAPK signaling
Insulin signaling stimulates the cellular growth/proliferation
through the MAPK pathway. It involves activation of GRB2 either
through IRS and/or SHC. GRB2 upon activation recruits SOS and initi-
ates the RAF phosphorylation signaling cascade and thereby activates
RAF, MEK and ERK [78]. Yuan Zhang et al. reported that metabolic
stress generated by amino acids deprivation causes the up-regulation
of ANGPTL8 through the RAS/RAF/MAPK pathway [19]. They demon-
strated the activation of Egr1 (Early growth response transcription
factor) by ANGPTL8 which in turn inhibits the ATGL (adipose triglyc-
eride lipase) enzyme.
3.8.8. ANGPTL8 signaling
The regulatory roles of ANGPTL8 have been discussed in detail
(see Sections 3.4–3.7) and will be briefly summarized here to com-
plete the overview of the newly designed pathway. ANGPTL8 has
been demonstrated to inhibit LPL and regulate the postprandial
trafficking of incoming lipids to the storage organs [5,14]. It also
regulates autophagy, adipogenesis and may be pancreatic beta cell
proliferation [7,8,16]. The interacting proteins from these pathways
with ANGPTL8 are yet to be identified. Therefore, we have linked out
the respective roles of ANGPTL8 to already existing pathways present
in WikiPathways in the ANGPTL8 regulatory pathway.
The construction of the ANGPTL8 regulatory pathway (Fig. 3) is
the first attempt to comprehensively integrate the current knowl-
edge of its regulation in a pathway. ANGPTL8 is associated with
several endocrine disorders such as diabetes, obesity and metabolic
syndrome and is gaining strength as a potential drug target for their
treatment [9,10,12,49]. In this regard, this pathway could increase
the comprehension of underlying physiological and physiopatholog-
ical regulation of ANGPTL8. It also increases our current understand-
ing of ANGPTL8 regulation. For example, an increase of ANGPTL8 in
the joint presence of insulin and glucose and not in the absence of
either raised a possibility that a crosstalk mechanism might regu-
late ANGPTL8 expression [8,13]. This crosstalk is now visible in the
ANGPTL8 regulatory pathway through interactions among different
transcription factors including ChREBP, SREBPs, LXR and TR regulat-
ing expression of ANGPTL8 under different metabolic arms of the
IS pathway. Specifically, the regulation of ChREBP and then subse-
quent regulation of ANGPTL8 through ChREBP requires the presence
of both insulin and glucose because the transcriptional and post-
translational regulation of ChREBP is itself dependent on various
entities from the IS pathway. Besides this, the complex regulation of
ANGPTL8 as viewed in the ANGPTL8 regulatory pathway is indicative
that ANGPTL8 lies at the core of lipid and glucose homeostasis and
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could act as a metabolic switch in positive energy balance conditions.
Therefore, more studies are required to decipher the precise dynam-
ics of this pathway in order to exploit the full potential of ANGPTL8
as a drug candidate in all of the related disorders.
4. Conclusion
ANGPTL8 is a novel hormone which has been reported to play role
in both glucose and lipid metabolic pathways. Its unique metabolic
nature allows viewing it as a potential drug target for many related
endocrine disorders. The current study provided an update to under-
stand its physiological function from literature curated findings.
Besides this, the ANGPTL8 regulatory pathway has been presented
as a research resource which is the first instance to map the inter-
action data of ANGPTL8 as interactive pathway. The pathway has
been made available to the research community for usage, feedback,
and updates at WikiPathways (Pathway Id: WP3915), an open source
interaction database. This pathway serves to increase our current
understanding of ANGPTL8 by allowing its visualization with respect
to other pathways. Moreover, the pathway also allows to observe the
crosstalk involved in the regulation of ANGPTL8, which was not pos-
sible before. This pathway could also assist the future omics-based
investigations in finding molecular targets/regulators of ANGPTL8 as
their analysis depend on the pathways data resources.
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